[go: up one dir, main page]

IS8567A - Efnasmíð á heterósýklískum efnasamböndum sem innihalda fimm- eða sex-atóma hringi - Google Patents

Efnasmíð á heterósýklískum efnasamböndum sem innihalda fimm- eða sex-atóma hringi

Info

Publication number
IS8567A
IS8567A IS8567A IS8567A IS8567A IS 8567 A IS8567 A IS 8567A IS 8567 A IS8567 A IS 8567A IS 8567 A IS8567 A IS 8567A IS 8567 A IS8567 A IS 8567A
Authority
IS
Iceland
Prior art keywords
nitrogen
halo
carbon
och2
excess
Prior art date
Application number
IS8567A
Other languages
English (en)
Other versions
IS2634B (is
Inventor
V. Schally Andrew
Attila Nagy
Cai Ren Zhi
Original Assignee
Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24247176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8567(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Administrators Of The Tulane Educational Fund filed Critical Administrators Of The Tulane Educational Fund
Publication of IS8567A publication Critical patent/IS8567A/is
Publication of IS2634B publication Critical patent/IS2634B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IS8567A 1995-11-27 2006-11-09 Efnasmíð á heterósýklískum efnasamböndum sem innihalda fimm- eða sex-atóma hringi IS2634B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/562,652 US5843903A (en) 1995-11-27 1995-11-27 Targeted cytotoxic anthracycline analogs
PCT/EP1996/005029 WO1997019954A1 (en) 1995-11-27 1996-11-14 Targeted cytotoxic anthracycline analogs

Publications (2)

Publication Number Publication Date
IS8567A true IS8567A (is) 2006-11-09
IS2634B IS2634B (is) 2010-06-15

Family

ID=24247176

Family Applications (2)

Application Number Title Priority Date Filing Date
IS4734A IS2178B (is) 1995-11-27 1998-05-05 Merktar frumueiturs-antrasýklín hliðstæður
IS8567A IS2634B (is) 1995-11-27 2006-11-09 Efnasmíð á heterósýklískum efnasamböndum sem innihalda fimm- eða sex-atóma hringi

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS4734A IS2178B (is) 1995-11-27 1998-05-05 Merktar frumueiturs-antrasýklín hliðstæður

Country Status (27)

Country Link
US (2) US5843903A (is)
EP (2) EP1384710B1 (is)
JP (2) JP3987575B2 (is)
KR (2) KR100445754B1 (is)
CN (2) CN1166597C (is)
AT (2) ATE401305T1 (is)
AU (1) AU709539B2 (is)
BR (1) BR9611647B1 (is)
CA (2) CA2471775C (is)
CZ (1) CZ297297B6 (is)
DE (2) DE69630233T2 (is)
DK (2) DK0863917T3 (is)
EA (1) EA001372B1 (is)
ES (2) ES2310222T3 (is)
HK (1) HK1052920B (is)
HU (1) HU229870B1 (is)
IL (3) IL134685A (is)
IS (2) IS2178B (is)
MX (1) MX9804119A (is)
NO (2) NO324035B1 (is)
NZ (1) NZ322054A (is)
PL (3) PL187230B1 (is)
PT (2) PT863917E (is)
SK (2) SK284392B6 (is)
UA (1) UA67722C2 (is)
WO (1) WO1997019954A1 (is)
ZA (1) ZA969709B (is)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
JP2002530059A (ja) 1998-11-13 2002-09-17 サイクラセル・リミテッド 輸送ベクター
FR2786397B1 (fr) * 1998-11-30 2003-01-10 Synt Em Vecteurs peptidiques de substances a travers la barriere hematoencephalique pour etre utilises dans le diagnostic ou la therapie d'une affection du snc
FR2786398B1 (fr) * 1998-11-30 2002-12-27 Synt Em Composition pharmaceutique anti-cancereuse et anti-chimioresistance comprenant un agent anticancereux et au moins un peptide
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6528481B1 (en) 1999-02-16 2003-03-04 The Burnam Institute NG2/HM proteoglycan-binding peptides that home to angiogenic vasculature and related methods
US6380161B1 (en) 1999-06-21 2002-04-30 Inkine Pharmaceutical Company, Inc. Compositions for treating chemotherapy-resistant tumor cells and targeted chemotherapy compositions
WO2001036007A2 (en) * 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions of a combination of radioactive therapy and cell-cycle inhibitors
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
EP1301540B1 (en) * 2000-04-26 2004-07-28 BioSynthema Inc. Rgd (arg-gly-asp) coupled to neuropeptides
US7420030B2 (en) 2000-09-08 2008-09-02 The Board Of Regents Of The University Of Texas System Aminopeptidase A (APA) targeting peptides for the treatment of cancer
US7452964B2 (en) 2001-09-07 2008-11-18 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides against placenta and adipose tissues
US20040170955A1 (en) 2000-09-08 2004-09-02 Wadih Arap Human and mouse targeting peptides identified by phage display
KR100420007B1 (ko) * 2001-04-25 2004-03-02 노영쇠 안트라사이클린 유도체 및 이를 포함하는 항암제
US7326685B2 (en) * 2001-09-21 2008-02-05 The Administrators Of The Tulane Educational Fund Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
AU2003224644A1 (en) * 2002-02-27 2003-09-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtan Conjugates of ligand, linker and cytotoxic agent and related compositions and methods of use
US7771727B2 (en) 2002-03-01 2010-08-10 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
JP5000848B2 (ja) * 2002-05-21 2012-08-15 第一三共株式会社 グレリン含有医薬組成物
EP1509256B1 (en) 2002-05-24 2009-07-22 Angiotech International Ag Compositions and methods for coating medical implants
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
BR0314743A (pt) 2002-09-26 2005-07-26 Angiotech Int Ag Envoltórios perivasculares
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
US20050043215A1 (en) 2003-02-19 2005-02-24 Tamara Minko Complex drug delivery composition and method for treating cancer
AU2007221964B2 (en) * 2003-04-22 2008-12-11 Ipsen Pharma S.A.S. Peptide vectors
CN1777439A (zh) * 2003-04-22 2006-05-24 研究及应用科学协会股份有限公司 生长抑素的载体
US7097993B2 (en) 2003-06-25 2006-08-29 Wisconsin Alumni Research Foundation Method for identifying an agent that modulates type 1 phosphatidylinositol phosphate kinase isoform β661 activity
WO2005086951A2 (en) * 2004-03-10 2005-09-22 Threshold Pharmaceuticals, Inc. Hypoxia-activated anti-cancer agents
US20070060534A1 (en) * 2005-06-30 2007-03-15 Threshold Pharmaceuticals, Inc. Anthracycline analogs
EP1900742A1 (en) 2006-09-07 2008-03-19 AEterna Zentaris GmbH Conjugates of disorazoles and their derivatives with cell-binding molecules, novel disorazole derivatives, processes of manufacturing and uses thereof
HRP20160631T1 (hr) * 2006-09-06 2016-07-15 Æterna Zentaris Gmbh Konjugati disorazola i njihovi derivati sa staničnovezajućim molekulama, novi derivati disorazola, postupci njihove pripreme i njihove uporabe
US20100087370A1 (en) * 2007-02-14 2010-04-08 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
RU2377247C2 (ru) * 2007-12-27 2009-12-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет Молекулярный конъюгат на основе синтетических аналогов люлиберина и его применение в качестве средства доставки днк в клетки гормон-чувствительных опухолей (варианты)
US8742076B2 (en) * 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
ES2655243T3 (es) * 2008-04-11 2018-02-19 Tianjin Hemay Oncology Pharmaceutical Co., Ltd Derivados antibióticos de antraciclina con alta actividad, métodos de preparación y usos de los mismos
CN101555264B (zh) * 2008-04-11 2014-09-03 天津和美生物技术有限公司 具有高活性的四环蒽醌类抗生素的衍生物及其制备和应用
AR072804A1 (es) 2008-07-15 2010-09-22 Genentech Inc Conjugados derivados de antraciclina,proceso para su preparacion,composiciones farmaceuticas que los contienen y su uso como agentes antitumorales.
MX2011008774A (es) * 2009-02-20 2011-10-24 Ipsen Pharma Sas Conjugados citotoxicos que tienen un compuesto de unión de receptores de neuropeptidos y.
CN102050856B (zh) * 2009-11-03 2014-04-30 天津和美生物技术有限公司 具有高活性的表阿霉素的衍生物及其制备和应用
BR112013013127B1 (pt) 2010-12-02 2021-06-22 Nerviano Medical Sciences S.R.L. Processo para a preparação de derivados de morfolinil antraciclina, compostos derivados de morfolinil antraciclina e composição farmacêutica compreendendo estes compostos
CN105198966B (zh) * 2014-06-26 2019-06-21 中国人民解放军军事医学科学院毒物药物研究所 GnRH类似物-细胞毒分子缀合物、其制备方法及用途
KR102062025B1 (ko) 2014-06-30 2020-01-03 타베다 세라퓨틱스, 인코포레이티드 표적화된 콘주게이트 및 입자 및 그것의 제형
EP3045540A1 (en) 2015-01-19 2016-07-20 Æterna Zentaris GmbH Enzymatic process for the regioselective manufacturing of N-Fmoc-doxorubicin-14-O-dicarboxylic acid mono esters
AU2016343817B2 (en) 2015-10-28 2021-05-27 Tva (Abc), Llc SSTR-targeted conjugates and particles and formulations thereof
US10450340B2 (en) 2017-02-16 2019-10-22 Monopar Therapeutics Inc. 3′-deamino-3′-(2″-pyrroline-1″-yl)-5-imino-13-deoxyanthracyclines and methods of preparation
CN120081907A (zh) * 2018-11-13 2025-06-03 省卫生服务机构 用于胃泌素释放肽受体（grpr）的体内成像和治疗grpr相关病症的放射性标记蛙皮素衍生化合物
JP2025510161A (ja) 2022-03-25 2025-04-14 プロビンシャル・ヘルス・サービシーズ・オーソリティ ガストリン放出ペプチド受容体（ｇｒｐｒ）のインビボイメージング及びｇｒｐｒ関連障害の治療のための放射性標識化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3725350A (en) * 1972-04-26 1973-04-03 Commercial Soluents Corp Polymeric substances comprising the reaction product of melamine, aldehyde and oxazolidines
US4299822A (en) * 1980-06-09 1981-11-10 Sidney Farber Cancer Institute, Inc. N-Trifluoroacetyladriamycin-14-O-hemiglutarate and -hemiadipate and therapeutic compositions containing same
US4464529A (en) * 1982-07-20 1984-08-07 Sri International Analogues of morpholinyl daunorubicin and morpholinyl doxorubicin
IL89220A (en) * 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5217955A (en) * 1989-09-15 1993-06-08 Biomeasure, Inc. Treatment of cancer with peptide analog of bombesin, grp, litorin or neuromedin
US5304687A (en) * 1989-12-19 1994-04-19 Farmitalia Carlo Erba S.R.L. Morpholinyl derivatives of doxorubicin and process for their preparation
ES2094136T3 (es) * 1989-12-19 1997-01-16 Pharmacia Spa Intermediarios quirales de 1,5-diyodo-2-metoxi o benciloxi.
DE69112684T2 (de) * 1990-04-06 1996-02-01 Univ Tulane LHRH-Analoge.
EP0450480B1 (en) * 1990-04-06 1995-06-21 The Administrators of The Tulane Educational Fund Somatostatin Analogues
JP3169425B2 (ja) * 1992-03-27 2001-05-28 三共株式会社 アジドペンタンサイクリトール
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates

Also Published As

Publication number Publication date
US5843903A (en) 1998-12-01
NO324035B1 (no) 2007-07-30
SK284672B6 (sk) 2005-08-04
KR20040037176A (ko) 2004-05-04
DE69630233D1 (de) 2003-11-06
EP1384710A1 (en) 2004-01-28
ATE251179T1 (de) 2003-10-15
PL191781B1 (pl) 2006-07-31
HK1052920B (zh) 2005-03-04
DE69637604D1 (de) 2008-08-28
IL119691A0 (en) 1997-02-18
PL326865A1 (en) 1998-10-26
PL188786B1 (pl) 2005-04-29
HUP9903771A3 (en) 2000-07-28
HU229870B1 (en) 2014-10-28
EP1384710B1 (en) 2008-07-16
IS4734A (is) 1998-05-05
WO1997019954A1 (en) 1997-06-05
MX9804119A (es) 1998-09-30
EP0863917A1 (en) 1998-09-16
EP0863917B1 (en) 2003-10-01
AU709539B2 (en) 1999-09-02
SK284392B6 (sk) 2005-03-04
NO20051111L (no) 2005-03-01
BR9611647A (pt) 1999-02-23
SK62898A3 (en) 1999-06-11
UA67722C2 (en) 2004-07-15
DE69630233T2 (de) 2004-08-05
NO982252D0 (no) 1998-05-15
BR9611647B1 (pt) 2010-03-09
CN1405127A (zh) 2003-03-26
HK1052920A1 (en) 2003-10-03
CA2471775A1 (en) 1997-06-05
PT1384710E (pt) 2008-10-08
CA2238574A1 (en) 1997-06-05
NZ322054A (en) 1999-04-29
CA2471775C (en) 2008-01-29
ES2310222T3 (es) 2009-01-01
JP3987575B2 (ja) 2007-10-10
KR19990071672A (ko) 1999-09-27
NO982252L (no) 1998-05-15
KR100467899B1 (ko) 2005-01-24
PL187230B1 (pl) 2004-06-30
CN1137136C (zh) 2004-02-04
DK0863917T3 (da) 2004-01-19
IS2178B (is) 2006-12-15
US6184374B1 (en) 2001-02-06
PT863917E (pt) 2004-02-27
DK1384710T3 (da) 2008-11-17
IL134685A (en) 2002-12-01
IL134685A0 (en) 2001-04-30
HUP9903771A2 (hu) 2000-02-28
EA001372B1 (ru) 2001-02-26
CN1166597C (zh) 2004-09-15
EA199800492A1 (ru) 1998-12-24
HK1017363A1 (en) 1999-11-19
JP2007045845A (ja) 2007-02-22
KR100445754B1 (ko) 2004-12-08
CN1202903A (zh) 1998-12-23
AU7572296A (en) 1997-06-19
JP4778405B2 (ja) 2011-09-21
CA2238574C (en) 2004-10-19
ATE401305T1 (de) 2008-08-15
JP2000502055A (ja) 2000-02-22
CZ135798A3 (cs) 1998-10-14
CZ297297B6 (cs) 2006-11-15
IS2634B (is) 2010-06-15
ES2205067T3 (es) 2004-05-01
IL119691A (en) 2002-02-10
ZA969709B (en) 1997-08-25

Similar Documents

Publication Publication Date Title
IS8567A (is) Efnasmíð á heterósýklískum efnasamböndum sem innihalda fimm- eða sex-atóma hringi
SE9301911D0 (sv) New peptide derivatives
HU9600963D0 (en) Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
PT80913A (en) Novel intermediate and method for its preparation
ES8603408A1 (es) Un procedimiento para la preparacion de un compuesto de 2-oxindol-1-carboxamida
ATE384063T1 (de) Sammlungen von verbindungen
MXPA06001274A (es) Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
NZ510489A (en) Pyrrolo-benzodiazine derivatives optionally linked to a solid support useful for treating gene based diseases or bacterial, parasitic and viral infections
IT1283782B1 (it) Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
HRP20000585B1 (en) Substituted bisindolymaleimides for the inhibition of cell proliferation
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
MY108849A (en) Novel compound
DE69737376D1 (de) Verfahren zur Synthese einer Oxonolverbindung
EA199900684A1 (ru) Производные иминоазаантрациклинона для лечения амилоидоза
HRP980646B1 (en) Novel oleandomycin derivatives
AR248396A1 (es) Procedimiento para la obtencion de 1, 5-diaril pirazoles utiles como antiinflamatorios y compuestos intermediarios para su uso exclusivo en el procedimiento.
MX9205408A (es) Metodo para tratar hipertension.
DE69528984D1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
RU95105338A (ru) Трициклические цефемсульфоны, способ их получения, композиция
AR015458A1 (es) Compuestos de tetrahidrofurano, y composicion farmaceutica que lo contiene.
DK316986A (da) Kemiske forbindelser, som er phosphodiesterase type iii inhibitorer
YU58300A (sh) Postupak za dobijanje 3-aminoalkohola
ES8301230A1 (es) Un procedimiento para la preparacion de 1-fenil-5-amidotetrazoles.
GEP19981168B (en) Benzimidazole derivatives and pharmaceutically acceptable salts thereof, intermediate compounds, method of their reception, stable crystals, a composition for inhibition of angiotensin ii
ECSP993154A (es) PROCEDIMIENTO PARA LA PREPARACION DE PIRAZOLO (4,3,d) -PIRIMIDIN -7-ONAS Y SUS INTERMEDIOS